STAT+: Pharmalittle: We’re reading about Novo Nordisk boosting consumer focus, FDA approving a gene therapy, and more
Why it matters: Big Pharma is adapting to consumer demands, while rare disease gene therapies gain ground with evolving FDA flexibility.
- Novo Nordisk appointed Mars CEO Poul Weihrauch as a board observer to enhance its consumer credentials and strengthen its position in the U.S. obesity market (Reuters).
- Novo Nordisk launched its Wegovy pill through multiple cash-pay channels, moving beyond traditional insurance routes to boost consumer access (Reuters).
- The FDA approved Rocket Pharma's Kresladi, a gene therapy for severe LAD-1, an ultra-rare disease causing life-threatening infections in children (STAT).
- Rocket Pharma initially faced FDA rejection for Kresladi in 2024 due to manufacturing concerns, but the agency has since shown willingness to relax some requirements for gene therapies (STAT).
- Kresladi's approval will earn Rocket Pharma an FDA priority review voucher, allowing for faster approval of another drug, despite the therapy not being a major revenue generator due to LAD-1's rarity (STAT).
Novo Nordisk is strategically bolstering its consumer focus in the competitive U.S. obesity market by appointing Mars CEO Poul Weihrauch to its board and diversifying its Wegovy distribution channels, according to Reuters. Simultaneously, the FDA has approved Rocket Pharma's Kresladi, a gene therapy for the ultra-rare LAD-1 disease, despite previous manufacturing concerns, as reported by STAT, signaling a potential shift in the agency's regulatory approach for such therapies.
